Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Dec 2021

Solanes-Casado Sonia, Cebrián Arancha, Rodríguez-Remírez María, Mahíllo Ignacio, García-García Laura, Río-Vilariño Anxo, Baños Natalia, de Cárcer Guillermo, Monfort-Vengut Ana, Castellano Víctor, Fernández-Aceñero Maria Jesús, García-Foncillas Jesús, Del Puerto-Nevado Laura

Abstract excerpt

New therapeutic targets are revolutionizing colorectal cancer clinical management, opening new horizons in metastatic patients' outcome. Polo Like Kinase1 (PLK1) inhibitors have high potential as antitumoral agents, however, the emergence of drug resistance is a major challenge for their use in clinical practice. Overcoming this challenge represents a hot topic in current drug discovery research. BI2536-resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Axl Receptor Tyrosine Kinase
Share to HCT116 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HT29 Cells

Share to Mevalonic Acid

Share to Polo-Like Kinase 1

Share to Pteridines

Share to Simvastatin

Share to Twist-Related Protein 1

Source

Identifiers

PMID: 34700228
DOI: 10.1016/j.biopha.2021.112347

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.PMID 34700228Read ↗

Andrographis overcomes 5-fluorouracil-associated chemoresistance through inhibition of DKK1 in colorectal cancerSemantic proximity Read ↗

Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistanceSemantic proximity Read ↗

In silico analysis to identify miR-1271-5p/PLCB4 (phospholipase C Beta 4) axis mediated oxaliplatin resistance in metastatic colorectal cancerSemantic proximity Read ↗

Modeling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtypeSemantic proximity Read ↗

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistanceSemantic proximity Read ↗

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read ↗

Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal CancerSemantic proximity Read ↗

Modelling oxaliplatin resistance in colorectal cancer reveals a <i>SERPINE1</i> -based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtypeSemantic proximity Read ↗

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read ↗

Targeting hexokinase 2 increases the sensitivity of oxaliplatin by Twist1 in colorectal cancerSemantic proximity Read ↗

Screening of a FDA-Approved Compound Library Identifies Menadione in Regulating Colon Cancer Programmed Death via MAPK8 CascadesSemantic proximity Read ↗

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.